INTRODUCTION {#s1}
============

Massively parallel sequencing (MPS) of the exome has demonstrated significant diagnostic and clinical utility in patients with suspected genetic disorders ([@MCS005231MILC25]; [@MCS005231MILC14]; [@MCS005231MILC33]; [@MCS005231MILC10]; [@MCS005231MILC16]). Molecular diagnostic rates from clinical testing by hospital and reference laboratories performing exome sequencing (ES) range from 24% to 58%, likely influenced by laboratory-specific methodologies and by the characteristics of the patient population being evaluated ([@MCS005231MILC10]). Given the utility of ES, it has been proposed that the assay should be considered as a first-tier molecular test ([@MCS005231MILC49]; [@MCS005231MILC16]). An additional advantage to this type of testing is the ability to reevaluate existing sequence data as advances in bioinformatic processing and variant detection occur over time. Furthermore, this approach allows for a consideration of the evolution of patient phenotype, in addition to the inclusion of updated/emerging data for disease--gene associations, thus further enhancing diagnostic potential ([@MCS005231MILC13]; [@MCS005231MILC36]).

The increased utilization of MPS, including ES, has expanded our understanding of the contribution of somatic mosaicism in genetic disorders by enhancing our ability to identify disease-associated variants at low variant allele frequency/fraction (VAF). Genetic variation acquired during embryogenesis and resulting in the establishment of two or more genetically distinct cell populations represents postzygotic mosaicism. Disease-causing variants can be confined to the germline (gonadal mosaicism), resulting in disease when passed on to subsequent offspring. Alternatively, a genetic variant can occur in the soma of a developing embryo (somatic mosaicism), with variable levels of the variant throughout the body dependent on cell lineage. In addition, a mosaic variant affecting both the soma and germline is referred to as gonosomal mosaicism ([@MCS005231MILC5]). The phenotypic spectrum of postzygotic somatic mosaicism can vary and is dependent upon timing of the manifestation of the variant during development, along with the proportion of cells harboring the variant and distribution across tissue types. Pathogenic variants at very low VAF in affected tissue can be sufficient to cause disease. For example, in diseases such as Sturge--Weber or vascular anomalies with overgrowth (e.g., Proteus syndrome or *PIK3CA*-related overgrowth spectrum \[PROS\]), the VAF of pathogenic variants in affected tissue has been reported as low as 1% ([@MCS005231MILC27]; [@MCS005231MILC46]; [@MCS005231MILC17]).

Among unselected clinical exome cohort studies of pediatric, and combined pediatric and adult populations, disease-associated mosaic variants were noted at a frequency of ∼1%--1.5% ([@MCS005231MILC53]; [@MCS005231MILC40]; [@MCS005231MILC9]). The frequency of mosaicism increases when examining for specific phenotypes. For example, in epilepsy-related neurodevelopmental disorders, 3% of the pathogenic variants identified by either an MPS epilepsy panel or ES were mosaic ([@MCS005231MILC50]). In certain disorders (e.g., McCune--Albright and PROS), mosaic variants are the primary mechanism of disease ([@MCS005231MILC2]; [@MCS005231MILC19]; [@MCS005231MILC17]).

We evaluated two years of clinical ES data from our laboratory within a pediatric tertiary care center to determine the characteristics of disease-associated variants within our cohort, as well as to compare the diagnostic yield reported by the laboratory versus the ordering clinical provider\'s interpretation of laboratory reported variant causality. We sought to evaluate the concordance of the molecular ES diagnostic rate generated by the laboratory with clinical provider-confirmed diagnoses recorded in the electronic medical record (EMR) to test if the laboratory workflow, including selection of genes relevant to the proband phenotype and subsequent variant assessment, resulted in meaningful results being reported back to the ordering provider. We further summarized the characteristics of these provider-confirmed causal variants and evaluated the contribution of mosaic variants to genetic disease within the context of these diagnoses.

RESULTS {#s2}
=======

Patient Cohort {#s2a}
--------------

In a consecutive 24-month period, proband (*n* = 357) and parental (when available, *n* = 601) peripheral blood samples were submitted for ES to The Steve and Cindy Rasmussen Institute for Genomic Medicine at Nationwide Children\'s Hospital, Columbus, Ohio. Two submitted parental samples were excluded because of nonpaternity. Cases represented 267 (74.8%) trio analyses of the proband plus both parental samples, 65 (18.2%) duo analyses of the proband and one parental sample, and 25 (7%) proband-only analyses. All cases were reviewed or referred by a clinical geneticist at the time of test order. The cohort consisted primarily of pediatric probands or young adults with symptoms that initially presented in childhood (average age = 7.2 yr, range 0--56 yr). A phenotype-informed approach was applied for tertiary analysis. The top 20 Human Phenotype Ontology (HPO) terms representing the most common clinician-provided phenotypic characteristics among probands in this population are shown in [Table 1](#MCS005231MILTB1){ref-type="table"}. Consistent with other ES cohorts, global developmental delay (73.4% of our cohort), abnormal facial shape (51.3%), and muscular hypotonia (51.0%) were the most frequently described features ([@MCS005231MILC25]; [@MCS005231MILC54]; [@MCS005231MILC14]).

###### 

Frequency of the top 20 Human Phenotype Ontology (HPO) terms used to describe features of 357 probands referred for exome sequencing

  HPO ID       HPO term                                  Number of probands (%)
  ------------ ----------------------------------------- ------------------------
  HP:0001263   Global developmental delay                262 (73.4)
  HP:0001999   Abnormal facial shape                     183 (51.3)
  HP:0001252   Muscular hypotonia                        182 (51.0)
  HP:0000750   Delayed speech and language development   157 (44.0)
  HP:0001270   Motor delay                               136 (38.1)
  HP:0002194   Delayed gross motor development           127 (35.6)
  HP:0001250   Seizures                                  119 (33.3)
  HP:0100543   Cognitive impairment                      98 (27.5)
  HP:0001508   Failure to thrive                         91 (25.5)
  HP:0004322   Short stature                             90 (25.2)
  HP:0007010   Poor fine motor coordination              77 (21.6)
  HP:0000252   Microcephaly                              74 (20.7)
  HP:0002020   Gastroesophageal reflux                   69 (19.3)
  HP:0000729   Autistic behavior                         69 (19.3)
  HP:0000717   Autism                                    59 (16.5)
  HP:0001290   Generalized hypotonia                     57 (16.0)
  HP:0001622   Premature birth                           56 (15.7)
  HP:0002019   Constipation                              56 (15.7)
  HP:0001510   Growth delay                              52 (14.6)
  HP:0002376   Developmental regression                  50 (14.0)

Genomic Analyses {#s2b}
----------------

The clinical laboratory reported variants as likely causal for the proband\'s phenotype for 128 genetic disorders among 123 probands (34.5%; 95% CI, 29.5%--39.6%). Ordering provider documentation in the EMR corroborated 115 instances of the variant(s) being attributed to the etiology of the proband phenotype for a provider-substantiated diagnostic yield of 32.2% (95% CI, 27.4%--37.3%). Two probands were found to have two separate genetic disorders, for a total of 117 clinically confirmed genetic diagnoses. Clinical laboratory diagnoses and provider-substantiated diagnoses had an overall concordance of 91.4% \[95% CI, 85.1%--95.6%\]. Of the 11 laboratory-reported genetic disorders not substantiated by clinician data in the EMR, five were due to insufficient overlap of features, four remained in the differential for further clinical evaluation as the proband features develop, and two had discordant inheritance patterns among affected/unaffected family members. A diagnosis was determined for 10/25 (40.0%) of the proband-only analyses, 10/65 (15.4%) duo analyses, and 95/267 (35.6%) trio analyses. The patterns of inheritance for the 117 diagnoses included 75 (64.1%) autosomal dominant, 25 (21.4%) autosomal recessive, and 17 (14.5%) X-linked ([Fig. 1](#MCS005231MILF1){ref-type="fig"}).

![Distribution of variant types for 117 provider-substantiated diagnoses identified by exome sequencing in a pediatric cohort. (SNV) Single-nucleotide variant.](MCS005231Mil_F1){#MCS005231MILF1}

Out of the 916 individuals consented for medically actionable findings, 29 individuals (3.2%) had variants meeting American College of Medical Genetics and Genomics (ACMG)/Association for Molecular Pathology (AMP) criteria supportive of a Pathogenic/Likely Pathogenic classification. Eight families demonstrated a proband--parent shared finding, whereas four probands and nine parents harbored events individually. Diseases represented by these findings were Loey--Dietz syndrome (4%), malignant hyperthermia susceptibility (10%), hypertrophic cardiomyopathy (10%), familial hypercholesterolemia (14%), arrhythmogenic right ventricular cardiomyopathy (14%), long QT syndromes (24%), and hereditary breast and ovarian cancer (24%).

Among 95 diagnostic ES trio studies, we identified 97 genetic disorders, of which the inheritance patterns were autosomal dominant (*n* = 62; 63.9%), autosomal recessive (*n* = 21; 21.7%), and X-linked (*n* = 14; 14.4%). Among the autosomal dominantly inherited diseases, 54 variants (87.1%) were confirmed as de novo, whereas nine (64.3%) of the X-linked inherited disorders were attributable to de novo variation. Overall, de novo variation accounted for 64.9% \[63/97, 95% CI, 54.6%--74.4%\] of the inheritance pattern of genetic disorders detected in trio ES.

Of the 117 disorders, genetic disease associations were diverse among this cohort with 65% of the identified disease-associated genetic loci unique to a single proband. Recurrently involved genetic loci included *CREBBP*, in which causal variants associated with Rubenstein--Taybi syndrome were identified in three probands. Additionally, four probands each had causal variants in *ANKRD11* and *IQSEC2*, associated with KBG syndrome and X-linked intellectual disability, respectively. Causal variants of provider-substantiated diagnoses are provided in [Table 2](#MCS005231MILTB2){ref-type="table"} and [Table 3](#MCS005231MILTB3){ref-type="table"}, with the most common HPO terms describing this cohort detailed in [Table 1](#MCS005231MILTB1){ref-type="table"}.

###### 

Summary of cases with a pathogenic or likely pathogenic mosaic variant in a proband or parental sample

  Case   Proband gender/age   Clinical phenotype                                                                                                                                                                                                                                                   Gene       Zygosity/VAF   Chromosome (hg19)                HGVS DNA and protein reference                       Variant type/predicted effect   Parent of origin/VAF   Relevant disease association                                                Supporting references
  ------ -------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ---------- -------------- -------------------------------- ---------------------------------------------------- ------------------------------- ---------------------- --------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------
  1      Male/6 mo            Failure to thrive, profound hypotonia, global developmental delay, microcephalic, bilateral esotropia, short palpebral fissures, protuberant tongue, sparse scalp hair, hypsarrhythmia by long-term electroencephalographic monitoring, delayed myelination on MRI   *ARX*      Mosaic (12%)   Chr X:25025232 C \> T            NM_139058.2 c.1444G \> A p.(Gly482Ser)               Substitution/missense           De novo                \(XL\) Early infantile epileptic encephalopathy 1                           [@MCS005231MILC48]; [@MCS005231MILC47]; [@MCS005231MILC15]; [@MCS005231MILC38]
  2      Male/11 yr           Generalized epilepsy, global developmental delay, intellectual disability, autism, attention deficit hyperactivity disorder, able to walk independently with orthotics and verbally communicate                                                                      *CDKL5*    Mosaic (17%)   Chr X:18602452 G \> A            NM_003159.2 c.533G \> A p.(Arg178Gln)                Substitution/missense           De novo                \(XL\) Early infantile epileptic encephalopathy 2                           [@MCS005231MILC3]; [@MCS005231MILC20]; [@MCS005231MILC32]; [@MCS005231MILC31]; [@MCS005231MILC50]; [@MCS005231MILC23]; [@MCS005231MILC37]
  3      Male/1 yr            Global developmental delay, seizures, chorea, hypotonia, short stature, poor feeding, ptosis, frontal bossing, micrognathia                                                                                                                                          *TRIP12*   Mosaic (12%)   Chr 2:230679862 G \> A           NM_004238.2 c.1540C \> T p.(Arg514Ter)               Substitution/nonsense           De novo                (AD) Clark--Baraitser syndrome                                              [@MCS005231MILC8]; [@MCS005231MILC55]; [@MCS005231MILC28]
  4      Male/7 yr            Localization-related partial epilepsy with complex partial seizures, nonambulatory, global developmental delay, postnatal growth retardation, intellectual disability, autism, hyperopia, chronic constipation, dysphagia                                            *IQSEC2*   Hemi (98%)     Chr X:53264051 G \> A            NM_001111125.2 c.3817C \> T p.(Gln1273Ter)           Substitution/nonsense           Mosaic mother (11%)    \(XL\) Mental retardation 1                                                 [@MCS005231MILC4]^a^; [@MCS005231MILC12]; [@MCS005231MILC39]; [@MCS005231MILC34]
  5      Female/8 yr          Global developmental delay, fine motor delay, hirsutism, agenesis of the corpus callosum, hypotonia, tethered spinal cord, exotropia, clubfoot, tall forehead, downslanting palpebral fissures, macrostomia                                                          *ARID1A*   Mosaic (19%)   Chr 1:27092947 G \> A            NM_139135.2 c.2879-1G \> A p.?                       Substitution/splicing           De novo                (AD) Coffin--Siris syndrome 2                                               [@MCS005231MILC51]; [@MCS005231MILC44]; [@MCS005231MILC52]
  6      Male/7 yr            Periventricular white matter changes on MRI, mild intellectual disability, global developmental delay, hypotonia, GERD, myopathic facies, thickened low-set ears, flared nasal alae, upturned nasal tip                                                              *ARID2*    Het (46%)      Chr 12: 46245833_46245834delAG   NM_152641.3 c.3927_3928delAG p.(Gly1310Glufs Ter5)   Deletion/frameshift             Mosaic mother (4%)     (AD) Coffin--Siris syndrome 6                                               [@MCS005231MILC51]; [@MCS005231MILC7]; [@MCS005231MILC6]
  7      Female/2 yr          Macrocephaly, hirsutism, global developmental delay, bilateral perisylvian polymicrogyria with mildly enlarged ventricles on MRI                                                                                                                                     *PIK3R2*   Mosaic (18%)   Chr 19:18273784G \> A            NM_005027.3 c.1117G \> A p.(Gly373Arg)               Substitution/missense           De novo                (AD) Megalencephaly- polymicrogyria-polydactyly- hydrocephalus syndrome 1   [@MCS005231MILC35]; [@MCS005231MILC42]; [@MCS005231MILC29]

(VAF) Variant allele frequency/fraction, (hemi) hemizygous, (het) heterozygous, (N/A) not applicable, (XL) X-linked, (AD) autosomal dominant, (MRI) magnetic resonance imaging, (GERD) gastroesophageal reflux disease.

^a^Case previously reported.

###### 

Summary of causal variants in a pediatric exome cohort

  Case                                            Study type   Gene         Chromosome (hg19)                                 HGVS DNA and protein reference                                Zygosity                                           Parent of origin   Relevant disease association                                                                                                                                                                                                                                                                Variant assessment   ACMG/AMP criteria met
  ----------------------------------------------- ------------ ------------ ------------------------------------------------- ------------------------------------------------------------- -------------------------------------------------- ------------------ ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- -------------------- -----------------------------------------------------
  Autosomal recessive (homozygous)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 
  8^a^                                            Trio         *AMPD2*      Chr 1:110172910 C \> T                            NM_001257360.1 c.2201C \> T p.(Pro734Leu)                     Hom                                                Mat/pat            (AR) Pontocerebellar hypoplasia, type 9 (OMIM: 615809); (AR) ?Spastic paraplegia 63 (OMIM: 615686)                                                                                                                                                                                          VUS                  PM2, PP3
                                                               *COL11A1*    Chr 1:103488375 C \> A                            NM_080629.2 c.1204G \> T p.(Glu402Ter)                        Hom                                                Mat/pat            (AD) Stickler syndrome, type II (OMIM: 604841) (AR) fibrochondrogenesis 1 (OMIM: 228520); (AD) Marshall syndrome (OMIM: 154780)                                                                                                                                                             Likely pathogenic    PVS1, PM2
  9                                               Trio         *AP4S1*      Chr 14:31542174 C \> T                            NM_001254727.1 c.289C \> T p.(Arg97Ter)                       Hom                                                Mat/pat            (AR) Spastic paraplegia 52, autosomal recessive (OMIM: 614067)                                                                                                                                                                                                                              Pathogenic           PVS1, PM2, PM3, PP1
  10                                              Trio         *HYLS1*      Chr 11:125769895 A \> G                           NM_145014.2 c.632A \> G p.(Asp211Gly)                         Hom                                                Mat/pat            (AR) Hydrolethalus syndrome (OMIM: 236680)                                                                                                                                                                                                                                                  Pathogenic           PS3, PM1, PS4_Moderate, PP1, PP3, PP5
  11                                              Trio         *IDUA*       Chr 4:996535 G \> A                               NM_000203.4 c.1205G \> A p.(Trp402Ter)                        Hom                                                Mat/pat            (AR) Mucopolysaccharidosis Ih (OMIM: 607014); (AR) mucopolysaccharidosis Ih/s (OMIM: 607015); (AR) Mucopolysaccharidosis Is (OMIM: 607016)                                                                                                                                                  Pathogenic           PVS1, PS3, PS4_Moderate, PP5
  12^a^                                           trio         *KERA*       Chr 12:91449224 G \> A                            NM_007035.3 c.835C \> T p.(Arg279Ter)                         Hom                                                Mat/pat            (AR) Cornea plana 2, autosomal recessive (OMIM: 217300)                                                                                                                                                                                                                                     Pathogenic           PVS1, PM2, PS4_Moderate, PP1
                                                               *POLR3B*     Chr 12:106850924 C \> T                           NM_018082.5 c.2302C \> T p.(Arg768Cys)                        Hom                                                Mat/pat            (AR) Leukodystrophy, hypomyelinating, 8, with or without oligodontia and/or hypogonadotropic hypogonadism (OMIM: 614381)                                                                                                                                                                    Likely Pathogenic    PM2, PM5, PP2, PP3
  13                                              Trio         *PARN*       Chr 16:14704607 G \> A                            NM_002582.3 c.448C \> T p.(Arg150Cys)                         Hom                                                Mat/pat            (AR) Dyskeratosis congenita, autosomal recessive 6 (OMIM: 616353)                                                                                                                                                                                                                           Likely Pathogenic    PM1, PM2, PS3_Moderate, PP3
  14                                              Singleton    *PYCR1*      Chr 17:79892603 C \> T                            NM_001282281.1 c.640G \> A p.(Ala214Thr)                      Hom                                                Unknown            (AR) Cutis laxa, autosomal recessive, type IIB (OMIM: 612940) (AR) Cutis laxa, autosomal recessive, type IIIB (OMIM: 614438)                                                                                                                                                                VUS                  PM1, PM2, PP3
  Autosomal recessive (compound heterozygous)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      
  15                                              Trio         *AP4M1*      Chr 7:99704117 C \> T                             NM_004722.3 c.1117C \> T p.(Gln373Ter)                        Het                                                Pat                (AR) Spastic paraplegia 50, autosomal recessive (OMIM: 612936)                                                                                                                                                                                                                              Pathogenic           PVS1, PM2, PM3
                                                               *AP4M1*      Chr 7:99704464 C \> T                             NM_004722.3 c.1321C \> T p.(Arg441Ter)                        Het                                                Mat                (AR) Spastic paraplegia 50, autosomal recessive (OMIM: 612936)                                                                                                                                                                                                                              Likely pathogenic    PM2, PM3, PP3, PP5
  16                                              Singleton    *HBB*        Chr 11:5248232 T \> A                             NM_000518.4 c.20A \> T p.(Glu7Val)                            Het                                                Unknown            (AR) Sickle cell anemia (OMIM: 603903)                                                                                                                                                                                                                                                      Pathogenic           PS3, PM3, PM5, PS4_Moderate, PP5
                                                               *HBB*        Chr 11:5246908 C \> T                             NM_000518.4 c.364G \> A p.(Glu122Lys)                         Het                                                Unknown            (AR) Sickle cell anemia (OMIM: 603903)                                                                                                                                                                                                                                                      Likely pathogenic    PS4, PM2, PM3, PP5
  17                                              Trio         *MED25*      Chr 19:50331716 G \> A                            NM_030973.3 c.316G \> A p.(Gly106Arg)                         Het                                                Pat                (AR) ?Charcot--Marie--Tooth disease, type 2B2 (OMIM: 605589); (AR) Base--Vanagait--Smirin--Yosef syndrome (OMIM: 616449)                                                                                                                                                                    Likely pathogenic    PM2, PM3, PP2, PM5
                                                               *MED25*      Chr 19:50338388_50338397 delACCACAAGCA            NM_030973.3 c.1628_1637delACCACAAGCA p.(Asn543ArgfsTer51)     Het                                                Mat                (AR) ?Charcot--Marie--Tooth disease, type 2B2 (OMIM: 605589); (AR) Basel--Vanagait--Smirin--Yosef syndrome (OMIM: 616449)                                                                                                                                                                   Likely pathogenic    PVS1, PM2
  18                                              Duo          *OPA1*       Chr 3:193374977 delA                              NM_130837.2 c.2287delA p.(Ser763ValfsTer15)                   Het                                                Unknown            (AR) Behr syndrome (OMIM: 210000); (AR) optic atrophy 1 (OMIM: 165500); (AR) optic atrophy plus syndrome (OMIM: 125250)                                                                                                                                                                     Pathogenic           PVS1, PM2
                                                               *OPA1*       Chr 3:193361167 A \> G                            NM_130837.2 c.1311A \> G p.(Ile437Met)                        Het                                                Mat                (AR) Behr syndrome (OMIM: 210000) ;(AR) optic atrophy 1 (OMIM: 165500); (AR) optic atrophy plus syndrome (OMIM: 125250)                                                                                                                                                                     VUS                  PM1, PM3, PP1, PP3; BS3
  19                                              Trio         *RYR1*       Chr 19:38951159 delG                              NM_000540.2 c.2505delG p.(Pro836LeufsTer48)                   Het                                                Pat                (AR) Minicore myopathy with external ophthalmoplegia (OMIM: 255320) (AD, AR) Central core disease (OMIM: 117000)                                                                                                                                                                            Pathogenic           PVS1, PM2, PP5
  20                                              Trio         *RYR1*       Chr 19:38987047 A \> G                            NM_000540.2 c.6664-2A \> G p.?                                Het                                                Pat                (AR) Minicore myopathy with external ophthalmoplegia (OMIM: 255320); (AD, AR) central core disease (OMIM: 117000)                                                                                                                                                                           Pathogenic           PVS1, PM2, PP3
                                                               *RYR1*       Chr 19.39075637 G \> A                            NM_000540.2 c.14701G \> A p.(Glu4901Lys)                      Het                                                Mat                (AR) Minicore myopathy with external ophthalmoplegia (OMIM: 255320); (AD, AR) central core disease (OMIM: 117000)                                                                                                                                                                           Likely pathogenic    PM1, PM3, PP2, PP3
  21                                              Trio         *SAMHD1*     Chr 20:35563513 C \> T                            NM_015474.3 c.428G \> A p.(Arg143His)                         Het                                                Mat                (AR) Aicardi--Goutieres syndrome 5 (OMIM: 612952)                                                                                                                                                                                                                                           Pathogenic           PS3, PM2, PM5, PP3, PP5
                                                               *SAMHD1*     Chr 20:35533834 A \> G                            NM_015474.3 c.1343T \> C p.(Ile448Thr)                        Het                                                Pat                (AR) Aicardi-Goutieres syndrome 5 (OMIM: 612952)                                                                                                                                                                                                                                            Likely pathogenic    PM2, PM3, PP3, PP4
  22                                              Duo          *SLC17A5*    Chr 6:74351533 T \> C                             NM_012434.4 c.406A \> G p.(Lys136Glu)                         Het                                                Unknown            (AR) Salla disease (OMIM: 604369); (AR) sialic acid storage disorder, infantile (OMIM: 269920)                                                                                                                                                                                              Pathogenic           PS3, PM2, PS4_Moderate, PP3, PP5
                                                               *SLC17A5*    Chr 6:74345115 A \> T                             NM_012434.4 c.809T \> A p.(Leu270Ter)                         Het                                                Mat                (AR) Salla disease (OMIM: 604369); (AR) sialic acid storage disorder, infantile (OMIM: 269920)                                                                                                                                                                                              Pathogenic           PVS1, PM2, PM3
  23                                              Trio         *SLC22A5*    Chr 5:131706028 G \> T                            NM_003060.3 c.364G \> T p.(Asp122Tyr)                         Het                                                Mat                (AR) Carnitine deficiency, systemic primary (OMIM: 212140)                                                                                                                                                                                                                                  Likely pathogenic    PS3, PM2, PM3, PP3
                                                               *SLC22A5*    Chr 5:131721062 C \> T                            NM_003060.3 c.695C \> T p.(Thr232Met)                         Het                                                Pat                (AR) Carnitine deficiency, systemic primary (OMIM: 212140)                                                                                                                                                                                                                                  Pathogenic           PS3, PM_PS4, PM2, PP3, PP5
  24                                              Trio         *SLC6A3*     Chr 5:1422127 C \> T                              NM_001044.4 c.656G \> A p.(Arg219His)                         Het                                                Mat                (AR) Parkinsonism-dystonia, infantile, 1 (OMIM: 613135)                                                                                                                                                                                                                                     VUS                  PM2, PP2, PP3
                                                               *SLC6A3*     Chr 5:1416253 C \> G                              NM_001044.4 c.991G \> C p.(Ala331Pro)                         Het                                                Pat                (AR) Parkinsonism-dystonia, infantile, 1 (OMIM: 613135)                                                                                                                                                                                                                                     VUS                  PM2, PP2, PP3
  25                                              Trio         *SRD5A2*     Chr 2:31758741 T \> C                             NM_000348.3 c.377A \> G p.(Gln126Arg)                         Het                                                Mat                (AR) Pseudovaginal perineoscrotal hypospadias (OMIM: 264600)                                                                                                                                                                                                                                Pathogenic           PS3, PM2, PM3, PS4_Moderate, PP1, PP5
                                                               *SRD5A2*     Chr 2:31758802 delG                               NM_000348.3 c.317delC p.(Pro106LeufsTer25)                    Het                                                Pat                (AR) Pseudovaginal perineoscrotal hypospadias (OMIM: 264600)                                                                                                                                                                                                                                Likely pathogenic    PVS1, PM2
  26                                              Trio         *TBCD*       Chr 17:80772747 G \> A                            NM_005993.4 c.1255G \> A p.(Gly419Arg)                        Het                                                Mat                (AR) Encephalopathy, progressive, early-onset, with brain atrophy and thin corpus callosum (OMIM: 617193)                                                                                                                                                                                   VUS                  PM2, PP3
                                                               *TBCD*       Chr 17:80882859\_ 80882861delGAG                  NM_005993.4 c.2305_2307delGAG p.(Glu769del)                   Het                                                Pat                (AR) Encephalopathy, progressive, early-onset, with brain atrophy and thin corpus callosum (OMIM: 617193)                                                                                                                                                                                   VUS                  PM2
  27                                              Trio         *TRNT1*      Chr 3:3189583 C \> G                              NM_182916.2 c.1057-7C \> G p.?                                Het                                                Pat                (AR) Retinitis pigmentosa and erythrocytic microcytosis (OMIM: 616959) (AR) Sideroblastic anemia with B-cell immunodeficiency, periodic fevers, and developmental delay (OMIM: 616084)                                                                                                      Likely pathogenic    PM2, PM3, PP3, PP5
                                                               *TRNT1*      Chr 3:3189779 A \> G                              NM_182916.2 c.1246A \> G p.(Lys416Glu)                        Het                                                Mat                (AR) Retinitis pigmentosa and erythrocytic microcytosis (OMIM: 616959); (AR) sideroblastic anemia with B-cell immunodeficiency, periodic fevers, and developmental delay (OMIM: 616084)                                                                                                     Likely pathogenic    PM2, PM3, PM_PS3
  28                                              Trio         *UBA5*       Chr 3:132379541 dupA                              NM_024818.3 c.160dupA p.(Ser54LysfsTer16)                     Het                                                Mat                (AR) Epileptic encephalopathy, early infantile, 44 (OMIM: 617132)                                                                                                                                                                                                                           Pathogenic           PVS1, PM1, PM2, PP3
                                                               *UBA5*       Chr 3:132384835 G \> A                            NM_024818.3 c.215G \> A p.(Arg72His)                          Het                                                Pat                (AR) Epileptic encephalopathy, early infantile, 44 (OMIM: 617132)                                                                                                                                                                                                                           Likely pathogenic    PM1, PM2, PM3, PP2
  Autosomal recessive (one SNV + one copy loss)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    
  29                                              Trio         *IFT140*     Chr 16:1642177 C \> T                             NM_014714.3 c.634G \> A p.(Gly212Arg)                         Hemi (suspected deletion on other allele)          Mat                (AR) Short-rib thoracic dysplasia 9 with or without polydactyly (OMIM: 266920); (AR) Retinitis pigmentosa 80 (OMIM: 617781)                                                                                                                                                                 Pathogenic           PVS1, PS3, PM2, PM3, PP3, PP5
  30                                              Trio         *NUBPL*      Chr 14:32319298 T \> C                            NM_025152.2 c.815-27T \> C p.?                                Hemi (∼400kb deletion on other allele, by array)   Mat                (AR) Mitochondrial complex I deficiency, nuclear type 21 (OMIM: 618242)                                                                                                                                                                                                                     Likely pathogenic    PS3, PP3, PP5; BS1
  Autosomal dominant                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               
  31                                              Trio         *ABCC9*      Chr 12:21995260 C \> T                            NM_020297.3 c.3461G \> A p.(Arg1154Gln)                       Het                                                De novo            (AD) Hypertrichotic osteochondrodysplasia (OMIM: 239850)                                                                                                                                                                                                                                    Pathogenic           PS1, PS2, PS3 PM2, PP2, PP3
  32                                              Trio         *ANKRD11*    Chr 16:89345988_89345989 insGGCTTCGG              NM_001256183.1 c.6968_6975dupCCCCGAAG p.(Ala2326ProfsTer14)   Het                                                De novo            (AD) KBG syndrome (OMIM: 148050)                                                                                                                                                                                                                                                            Pathogenic           PVS1, PS2, PM2
  33                                              Trio         *ANKRD11*    Chr 16:89349005delC                               NM_001256182.1 c.3948delG p.(Leu1317Ter)                      Het                                                De novo            (AD) KBG syndrome (OMIM: 148050)                                                                                                                                                                                                                                                            Pathogenic           PVS1, PS2, PM2, PM4
  34                                              Trio         *ANKRD11*    Chr 16:89351049\_ 89351053delGTTTT                NM_001256182.1 c.1903_1907delAAACA p.(Lys635GlnfsTer26)       Het                                                De novo            (AD) KBG syndrome (OMIM: 148050)                                                                                                                                                                                                                                                            Pathogenic           PVS1, PS2, PM2, PS4_Moderate, PP1, PP5
  35                                              Singleton    *ANKRD11*    Chr 16:89351049\_ 89351053delGTTTT                NM_001256182.1 c.1903_1907delAAACA p.(Lys635GlnfsTer26)       Het                                                Unknown            (AD) KBG syndrome (OMIM: 148050)                                                                                                                                                                                                                                                            Pathogenic           PVS1, PS2, PM2, PS4_Moderate, PP1, PP5
  36                                              Trio         *ABCC9*      Chr 12:21995375 G \> A                            NM_005691.3 c.3346C \> T p.(Arg1116Cys)                       Het                                                Mat                (AD) Hypertrichotic osteochondrodysplasia (OMIM: 610253)                                                                                                                                                                                                                                    Likely pathogenic    PM2, PM5, PP2, PP3, PP5
  37                                              Trio         *ACTB*       Chr 7:5568223 G \> T                              NM_001101.3 c.491C \> A p.(Pro164His)                         Het                                                De novo            (AD) ?Dystonia, juvenile-onset (OMIM: 607371); (AD) Baraitser--Winter syndrome 1 (OMIM: 243310)                                                                                                                                                                                             Likely pathogenic    PS2, PM2, PP2, PP3
  38                                              Trio         *ARID1B*     Chr 6:157528657 C \> T                            NM_020732.3 c.6382C \> T p.(Arg2128Ter)                       Het                                                De novo            (AD) Coffin--Siris syndrome 1 (OMIM: 135900)                                                                                                                                                                                                                                                Pathogenic           PVS1, PS2, PM2, PP5
  39                                              Trio         *ATP6V1A*    Chr 3:113508666 G \> A                            NM_001690.3 c.967A \> G p.(Arg323Gly)                         Het                                                De novo            (AD) Epileptic encephalopathy, infantile or early childhood, 3 (OMIM: 618012)                                                                                                                                                                                                               Pathogenic           PS2, PM1, PM2, PP2, PP3
  40                                              Trio         *CACNA1C*    Chr 12:2566837 T \> C                             NM_199460.3 c.722T \> C p.(Val241Ala)                         Het                                                De novo            (AD) Timothy syndrome (OMIM: 601005); (AD) Brugada syndrome 3 (OMIM: 611875)                                                                                                                                                                                                                Likely pathogenic    PS2, PM1, PM2, PP3
  41                                              Trio         *CAMTA1*     Chr 1:7798409_7798411 delinsGTGCTGC               NM_015215.3 c.4049_4051delinsGTGCTGC p.(Pro1350ArgfsTer18)    Het                                                Mat                (AD) Cerebellar ataxia, nonprogressive, with mental retardation (OMIM: 614756)                                                                                                                                                                                                              Pathogenic           PVS1, PM2, PP1
  42                                              Trio         *CAV3*       Chr 3:8787396 T \> A                              NM_001234.4 c.299T \> A p.(Ile100Asn)                         Het                                                De novo            (AD) Cardiomyopathy, familial hypertrophic (OMIM: 192600); (AD) creatine phosphokinase, elevated serum (OMIM: 123320); (AD) long QT syndrome 9 (OMIM: 611818); (AD) myopathy, distal, Tateyama type (OMIM: 614321); (AD) rippling muscle disease (OMIM: 606072)                             Likely pathogenic    PS2, PM1, PM2, PP3
  43                                              Trio         *CCND2*      Chr 12:4409144 C \> A                             NM_001759.3 c.839C \> A p.(Thr280Asn)                         Het                                                De novo            (AD) Megalencephaly-polymicrogyria-polydactyly-hydrocephalus syndrome 3 (OMIM: 615938)                                                                                                                                                                                                      Pathogenic           PS2, PM1, PM2, PS4_Moderate, PP5
  44                                              Duo          *CHD2*       Chr 15:93485148 dupT                              NM_001271.3 c.789dupT p.(Glu264Ter)                           Het                                                Unknown            (AD) Epileptic encephalopathy, childhood-onset (OMIM: 615369)                                                                                                                                                                                                                               Likely pathogenic    PVS1, PM2
  45                                              Trio         *CHD7*       Chr 8:61773555_61773556 delAC                     NM_017780.3 c.7701_7702delAC p.(Arg2568AspfsTer7)             Het                                                De novo            (AD) CHARGE syndrome (OMIM: 214800); (AD) hypogonadotropic hypogonadism 5 with or without anosmia (OMIM: 612370)                                                                                                                                                                            Pathogenic           PVS1, PS2, PM2
  46                                              Singleton    *COL3A1*     Chr 2:189856222 G \> T                            NM_000090.3 c.862G \> T p.(Gly288Cys)                         Het                                                Unknown            (AD) Ehlers--Danlos syndrome, vascular type (OMIM: 130050)                                                                                                                                                                                                                                  Likely pathogenic    PM1, PM2, PP2, PP3
  47                                              Trio         *CREBBP*     Chr 16:3779691 C \> T                             NM_004380.2 c.5357G \> A p.(Arg1786His)                       Het                                                De novo            (AD) Rubinstein--Taybi syndrome 1 (OMIM: 180849)                                                                                                                                                                                                                                            Likely pathogenic    PS2, PM1, PM2, PP3
  48                                              Trio         *CREBBP*     Chr 16:3789597 C \> A                             NM_004380.2 c.4262G \> T p.(Cys1421Phe)                       Het                                                De novo            (AD) Rubinstein--Taybi syndrome 1 (OMIM: 180849)                                                                                                                                                                                                                                            Likely pathogenic    PS2, PM1, PM2, PP3
  49                                              Trio         *CREBBP*     Chr 16:3842042 G \> A                             NM_004380.2 c.1270C \> T p.(Arg424Ter)                        Het                                                De novo            (AD) Rubinstein--Taybi syndrome 1 (OMIM: 180849)                                                                                                                                                                                                                                            Pathogenic           PVS1, PS2, PM2, PP5
  50                                              Trio         *CSNK2A1*    Chr 20:476405 A \> T                              NM_177559.2 c.468T \> A p.(Asp156Glu)                         Het                                                De novo            (AD) Okur--Chung neurodevelopmental syndrome (OMIM: 617062)                                                                                                                                                                                                                                 Pathogenic           PS2, PM1, PM2, PM5, PP2, PP3, PP5
  51                                              Trio         *CSNK2A1*    Chr 20:485826 T \> C                              NM_177559.2 c.149A \> G p.(Tyr50Cys)                          Het                                                De novo            (AD) Okur--Chung neurodevelopmental syndrome (OMIM: 617062)                                                                                                                                                                                                                                 Pathogenic           PS2, PM2, PM5, PP2, PP5
  52                                              Trio         *DYRK1A*     Chr 21:38862468\_ 38862472 delCTCTT               NM_101395.2 c.665-9_665-5delCTCTT p.?                         Het                                                De novo            (AD) Mental retardation, autosomal dominant 7 (OMIM: 614104)                                                                                                                                                                                                                                Likely pathogenic    PS2, PM2, PP5
  53                                              Singleton    *EFTUD2*     Chr 17:42964119 C \> G                            NM_004247.3 c.106-1G \> C p.?                                 Het                                                Unknown            (AD) Mandibulofacial dysostosis, Guion--Almeida type (OMIM: 610536)                                                                                                                                                                                                                         Pathogenic           PVS1, PM2, PP3
  54                                              Duo          *EHMT1*      Chr 9:140637869 dupA                              NM_024757.4 c.870dupA p.(Arg291ThrfsTer7)                     Het                                                Unknown            (AD) Kleefstra syndrome 1 (OMIM: 610253)                                                                                                                                                                                                                                                    Likely pathogenic    PVS1, PM2
  55                                              Trio         *EHMT1*      Chr 9:140672394 dupC                              NM_024757.4 c.2079dupC p.(Glu694ArgfsTer4)                    Het                                                De novo            (AD) Kleefstra syndrome 1 (OMIM: 610253)                                                                                                                                                                                                                                                    Pathogenic           PVS1, PS2, PM2
  56                                              Trio         *FLG*^*b*^   Chr 1:152285861 G \> A                            NM_002016.1 c.1501C \> T p.(Arg501Ter)                        Het                                                Mat                (AD) Ichthyosis vulgaris (OMIM: 146700); (AD) {Dermatitis, atopic, susceptibility to, 2} (OMIM: 605803)                                                                                                                                                                                     Pathogenic           PVS1, PM3, PP5
                                                               *FLG*^*b*^   Chr 1:152285081\_ 152285084delACGT                NM_002016.1 c.2282_2285delCAGT p.(Ser761CysfsTer36)           Het                                                Pat                (AD) Ichthyosis vulgaris (OMIM: 146700); (AD) {Dermatitis, atopic, susceptibility to, 2} (OMIM: 605803)                                                                                                                                                                                     Pathogenic           PVS1, PS4, PM3, PP1
  57                                              Trio         *FLG*^*b*^   Chr 1:152285861 G \> A                            NM_002016.1 c.1501C \> T p.(Arg501Ter)                        Het                                                Pat                (AD) Ichthyosis vulgaris (OMIM: 146700); (AD) {Dermatitis, atopic, susceptibility to, 2} (OMIM: 605803)                                                                                                                                                                                     Pathogenic           PVS1, PS3, PP1, PP5
  58                                              Trio         *FOXG1*      Chr 14:29237138 A \> G                            NM_005249.4 c.653A \> G p.(Tyr218Cys)                         Het                                                De novo            (AD) Rett syndrome, congenital variant (OMIM: 613454)                                                                                                                                                                                                                                       Likely pathogenic    PS2, PM2, PP3
  59                                              Trio         *FOXP1*      Chr 3:71026799\_ 71026802delTAAT                  NM_001244810.1 c.1420_1423delATTA p.(Ile474GlyfsTer12)        Het                                                De novo            (AD) Mental retardation with language impairment and with or without autistic features (OMIM: 613670)                                                                                                                                                                                       Pathogenic           PVS1, PS2, PM2
  60                                              Duo          *GABRB2*     Chr 5:160758119 A \> G                            NM_021911.2 c.848T \> C p.(Leu283Pro)                         Het                                                Unknown            (AD) Epileptic encephalopathy, infantile or early childhood, 2 (OMIM: 617829)                                                                                                                                                                                                               VUS                  PM1, PM2, PP3
  61                                              Trio         *GABRB3*     Chr 15:27017618 T \> A                            NM_000814.5 c.173-2A \> T p.?                                 Het                                                De novo            (AD) Epileptic encephalopathy, early infantile, 43 (OMIM: 617113)                                                                                                                                                                                                                           Likely pathogenic    PS2, PM2, PP3
  62                                              Trio         *GABRG2*     Chr 5:161569244 C \> T                            NM_198903.2 c.964C \> T p.(Pro322Ser)                         Het                                                De novo            (AD) Epilepsy, generalized, with febrile seizures plus, type 3 (OMIM: 607681); (AD) epileptic encephalopathy, early infantile, 74 (OMIM: 618396)                                                                                                                                            Pathogenic           PS2, PS3, PM2, PM5, PP2, PP3, PP5
  63                                              Singleton    *HNRNPK*     Chr 9:86586597 dupT                               NM_031263.3 c.998dupA p.(Tyr333Ter)                           Het                                                Unknown            (AD) Au--Kline syndrome (OMIM: 616580)                                                                                                                                                                                                                                                      Pathogenic           PVS1, PS2, PM2, PP5
  64                                              Trio         *HRAS*       Chr 11:534289 C \> T                              NM_005343.2 c.34G \> A p.(Gly12Ser)                           Het                                                De novo            (AD) Costello syndrome (OMIM: 218040); (AD) Congenital myopathy with excess of muscle spindles (OMIM: 218040)                                                                                                                                                                               Pathogenic           PS2, PM1, PM2, PM5, PP5
  65                                              Trio         *KANSL1*     Chr 17:44248468 G \> A                            NM_001193465.1 c.1042C \> T p.(Arg348Ter)                     Het                                                De novo            (AD) Koolen--De Vries syndrome (OMIM: 610443)                                                                                                                                                                                                                                               Pathogenic           PVS1, PS2, PM2, PP5
  66                                              Singleton    *KMT2D*      Chr 12:49436599 G \> A                            NM_003482.3 c.5707C \> T p.(Arg1903Ter)                       Het                                                Unknown            (AD) Kabuki syndrome 1 (OMIM: 147920)                                                                                                                                                                                                                                                       Pathogenic           PVS1, PM2, PM6, PP3, PP5
  67                                              Trio         *MED13L*     Chr 12:116452999_116453015 delTCTTTGGACTGTGCATC   NM_015335.4 c.1077_1093del p.(Met359IlefsTer38)               Het                                                De novo            (AD) Mental retardation and distinctive facial features with or without cardiac defects (OMIM: 616789); (AD) transposition of the great arteries, dextro-looped 1 (OMIM: 608808)                                                                                                            Pathogenic           PVS1, PS2, PM2
  68                                              Trio         *MYT1L*      Chr 2:1915819 A \> T                              NM_015025.3 c.1676T \> A p.(Val559Asp)                        Het                                                De novo            (AD) Mental retardation, autosomal dominant 39 (OMIM: 616521)                                                                                                                                                                                                                               Pathogenic           PS2, PM1, PM2, PP3, PP2
  69                                              Trio         *MYT1L*      Chr 2:1906916 A \> T                              NM_001303052.1 c.1968T \> A p.(Tyr656Ter)                     Het                                                De novo            (AD) Mental retardation, autosomal dominant 39 (OMIM: 616521)                                                                                                                                                                                                                               Pathogenic           PVS1, PS2, PM2
  70                                              Trio         *NBEA*       Chr 13:35923346\_ 35923347delAG                   NM_015678.4 c.6005_6006delAG p.(Glu2002ValfsTer2)             Het                                                De novo            (AD) Seizures and intellectual disability (no OMIM) (PMID:28554332)                                                                                                                                                                                                                         VUS                  PM2, PS2_Moderate, PP3
  71                                              Trio         *NEDD4L*     Chr 18:56033460 C \> G                            NM_001144967.2 c.2063C \> G p.(Thr688Arg)                     Het                                                Mat                (AD) Periventricular nodular heterotopia 7 (OMIM: 617201)                                                                                                                                                                                                                                   VUS                  PM1, PM2, PP3
  72                                              Trio         *NOTCH1*     Chr 9:139399384\_ 139399385insTG                  NM_017617.3 c.4758_4759insCA p.(Asn1587GlnfsTer30)            Het                                                Pat                (AD) Adams--Oliver syndrome 5 (OMIM: 616028); (AD) aortic valve disease 1 (OMIM: 109730)                                                                                                                                                                                                    Likely pathogenic    PVS1, PM2
  73                                              Trio         *NSD2*       Chr 4:1906053 G \> A                              NM_133330.2 c.708G \> A p.(Trp236Ter)                         Het                                                De novo            (AD) Wolf--Hirchhorn syndrome--like (PMID: 31171569, 29884796)                                                                                                                                                                                                                              Pathogenic           PVS1, PS2, PM2, PP3
  74                                              Trio         *NSD2*       Chr 4:1936884dupG                                 NM_133330.2 c.1569dupG p.(Lys524GlufsTer17)                   Het                                                De novo            (AD) Wolf--Hirchhorn syndrome--like (PMID: 31171569, 29884796)                                                                                                                                                                                                                              Pathogenic           PVS1, PS2, PM2
  75                                              Trio         *NSD2*       Chr 4:1918630 C \> T                              NM_133330.2 c.793C \> T p.(Gln265Ter)                         Het                                                De novo            (AD) Wolf--Hirchhorn syndrome--like (PMID: 31171569, 29884796)                                                                                                                                                                                                                              Pathogenic           PVS1, PS2, PM2
  76                                              Trio         *PPP2R5D*    Chr 6:42975698 A \> C                             NM_006245.3 c.752A \> C p.(Asp251Ala)                         Het                                                De novo            (AD) Mental retardation, autosomal dominant 35 (OMIM: 616355)                                                                                                                                                                                                                               Pathogenic           PS2, PM2, PM5, PP2, PP3
  77                                              Singleton    *PTPN11*     Chr 12:112888172 A \> G                           NM_002834.3 c.188A \> G p.(Tyr63Cys)                          Het                                                Unknown            (AD) Noonan syndrome 1 (OMIM: 163950); (AD) LEOPARD syndrome 1 (OMIM: 151100); (AD) metachondromatosis (OMIM: 156250)                                                                                                                                                                       Pathogenic           PS1, PS3, PS4, PP1_Strong, PM1, PP2, PP3
  78                                              Trio         *PTPN11*     Chr 12:112915523 A \> G                           NM_002834.3 c.922A \> G p.(Asn308Asp)                         Het                                                De novo            (AD) Noonan syndrome 1 (OMIM: 163950); (AD) LEOPARD syndrome 1 (OMIM: 151100); (AD) metachondromatosis (OMIM: 156250)                                                                                                                                                                       Pathogenic           PS2_VERYStrong, PS3, PS4, PP1_Strong, PM1, PP2, PP3
  79                                              Trio         *PUF60*      Chr 8:144898801 dupA                              NM_078480.2 c.1569dupT p.(Glu524Ter)                          Het                                                De novo            (AD) Verheij syndrome (OMIM: 615583)                                                                                                                                                                                                                                                        Pathogenic           PVS1, PS2, PM2
  80                                              Singleton    *RAI1*       Chr 17:17700943 C \> T                            NM_030665.3 c.4681C \> T p.(Arg1561Ter)                       Het                                                Unknown            (AD) Smith--Magenis syndrome (OMIM: 182290)                                                                                                                                                                                                                                                 Pathogenic           PVS1, PM2, PP3
  81                                              Trio         *SALL1*      Chr 16:51174260 C \> A                            NM_002968.2 c.1873G \> T p.(Glu625Ter)                        Het                                                Pat                (AD) Towne--Brocks syndrome 1 (OMIM: 107480)                                                                                                                                                                                                                                                Pathogenic           PVS1, PM2, PP1, PP3
  82                                              Trio         *SATB2*      Chr 2:200193509 T \> G                            NM_015265.3 c.1298A \> C p.(Tyr433Ser)                        Het                                                De novo            (AD) Glass syndrome (OMIM: 612313)                                                                                                                                                                                                                                                          Likely pathogenic    PS2, PM1, PM2, PP2
  83                                              Trio         *SATB2*      Chr 2:200188564 delG                              NM_015265.3 c.1504delC p.(Gln502LysfsTer44)                   Het                                                De novo            (AD) Glass syndrome (OMIM: 612313)                                                                                                                                                                                                                                                          Pathogenic           PVS1, PS2, PM1, PM2
  84                                              Trio         *SCN1A*      Chr 2:166850875 T \> C                            NM_001202435.1 c.4633A \> G p.(Ile1545Val)                    Het                                                De novo            (AD) Epilepsy, generalized, with febrile seizures plus, type 2 (OMIM: 604403); (AD) epileptic encephalopathy, early infantile, 6 (Dravet syndrome) (OMIM: 607208); (AD) febrile seizures, familial, 3A (OMIM: 604403); (AD) migraine, familial hemiplegic, 3 (OMIM: 609634)                 Pathogenic           PS2, PM1, PM2, PP2, PP3
  85                                              Trio         *SCN8A*      Chr 12:52159459 G \> A                            NM_014191.3 c.2549G \> A p.(Arg850Gln)                        Het                                                De novo            (AD) Cognitive impairment with or without cerebellar ataxia (OMIM: 614306); (AD) epileptic encephalopathy, early infantile, 13 (OMIM: 614558); (AD) seizures, benign familial infantile, 5 (OMIM: 617080)                                                                                   Pathogenic           PS2, PM1, PM2, PP2, PP3, PP5
  86                                              Duo          *SERPINC1*   Chr 1:173879999 T \> C                            NM_000488.3 c.655A \> G p.(Asn219Asp)                         Het                                                Mat                (AD,AR) Thrombophilia due to antithrombin III deficiency (OMIM: 613118)                                                                                                                                                                                                                     Likely pathogenic    PM2, PM5, PS4_Moderate, PP2, PP3
  87                                              Trio         *SETD5*      Chr 3:9483407 A \> G                              NM_001292043.1 c.647A \> G p.(Asn216Ser)                      Het                                                De novo            (AD) Mental retardation, autosomal dominant 23 (OMIM: 615761)                                                                                                                                                                                                                               Likely pathogenic    PS2, PM2, PP3, BP1
  88                                              Trio         *SHANK3*     Chr 22:51160025\_ 51160037 delGGGCCCAGCCCCC       NM_033517.1 c.3764_3776del p.(Arg1255LeufsTer25)              Het                                                De novo            (AD) Phelan--McDermid syndrome (OMIM: 606232)                                                                                                                                                                                                                                               Pathogenic           PVS1, PS2, PM2
  89                                              Trio         *SLC2A1*     Chr 1:43394689 G \> A                             NM_006516.2 c.988C \> T p.(Arg330Ter)                         Het                                                De novo            (AD,AR) GLUT1 deficiency syndrome 1, infantile onset, severe (OMIM: 606777); (AD) GLUT1 deficiency syndrome 2, childhood onset (OMIM: 612126); (AD) dystonia 9 (OMIM: 601042); (AD) Stomatin-deficient cryohydrocytosis with neurologic defects (OMIM: 608885)                              Pathogenic           PVS1, PS2, PM2, PP3, PP5
  90                                              Trio         *SLC2A1*     Chr 1:43394649 dupC                               NM_006516.2 c.1028dupG p.(Met344HisfsTer37)                   Het                                                De novo            (AD,AR) GLUT1 deficiency syndrome 1, infantile onset, severe (OMIM: 606777); (AD) GLUT1 deficiency syndrome 2, childhood onset (OMIM: 612126); (AD) dystonia 9 (OMIM: 601042); (AD) Stomatin-deficient cryohydrocytosis with neurologic defects (OMIM: 608885)                              Pathogenic           PVS1, PS2, PM2
  91                                              Trio         *SMAD4*      Chr 18:48604676 A \> G                            NM_005359.5 c.1498A \> G p.(Ile500Val)                        Het                                                De novo            (AD) Myhre syndrome (OMIM: 139210); (AD) juvenile polyposis/hereditary hemorrhagic telangiectasia syndrome (OMIM: 175050); (AD) polyposis, juvenile intestinal (OMIM: 174900)                                                                                                               Pathogenic           PS2, PS3, PM1, PM2, PM5, PP2, PP3, PP5
  92                                              Trio         *SON*        Chr 21:34929623 G \> A                            NM_138927.3 c.6321 + 1G \> A p.?                              Het                                                De novo            (AD) ZTTK syndrome (OMIM: 617140)                                                                                                                                                                                                                                                           Pathogenic           PVS1, PS2, PM2
  93                                              Trio         *STXBP1*     Chr 9:130440731\_ 130440740dup AAGCCGGAGC         NM_003165.3 c.1381_1390dupAAGCCGGAGC p.(Arg464GlnfsTer31)     Het                                                De novo            (AD) Epileptic encephalopathy, early infantile, 4 (OMIM: 612164)                                                                                                                                                                                                                            Pathogenic           PVS1, PS2, PM2
  94                                              Trio         *STXBP1*     Chr 9:130440777 C \> G                            NM_003165.3 c.1427C \> G p.(Ser476Ter)                        Het                                                De novo            (AD) Epileptic encephalopathy, early infantile, 4 (OMIM: 612164)                                                                                                                                                                                                                            Pathogenic           PVS1, PS2, PM2
  95                                              Duo          *SYNGAP1*    Chr 6:33411735 C \> T                             NM_006772.2 c.3406C \> T p.(Gln1136Ter)                       Het                                                Unknown            (AD) Mental retardation, autosomal dominant 5 (OMIM: 612621)                                                                                                                                                                                                                                Likely pathogenic    PVS1, PM2
  96                                              Trio         *TBL1XR1*    Chr 3:176767798 G \> A                            NM_024665.4 c.689C \> T p.(Ser230Phe)                         Het                                                De novo            (AD) Mental retardation, autosomal dominant 41 (OMIM: 616944) (AD) Pierpont syndrome (OMIM: 602342)                                                                                                                                                                                         Likely pathogenic    PS2, PM2, PP2, PP3
  97                                              Trio         *TBX1*       Chr 22:19750829 T \> C                            NM_005992.1 c.476T \> C p.(Leu159Pro)                         Het                                                De novo            (AD) DiGeorge syndrome (OMIM: 188400); (AD) tetralogy of Fallot (OMIM: 187500); (AD) velocardiofacial syndrome (OMIM: 192430)                                                                                                                                                               Likely pathogenic    PS2, PM2, PP3
  98                                              Trio         *TCF4*       Chr 18:52921925 G \> A                            NM_001243226.2 c.1459C \> T p.(Arg487Ter)                     Het                                                De novo            (AD) Corneal dystrophy, Fuchs endothelial, 3 (OMIM: 613267); (AD) Pitt--Hopkins syndrome (OMIM: 610954)                                                                                                                                                                                     Pathogenic           PVS1, PS2, PS3, PM2, PS4_Moderate
  99                                              Duo          *TUBB4A*     Chr 19:6495765 C \> T                             NM_001289123.1 c.898G \> A p.(Asp300Asn)                      Het                                                Unknown            (AD) Dystonia 4, torsion, autosomal dominant (OMIM: 128101); (AD) leukodystrophy, hypomyelinating, 6 (OMIM: 612438)                                                                                                                                                                         Pathogenic           PS2, PS3, PM1, PM2, PP2, PP3
  100                                             Trio         *ZEB2*       Chr 2:145156329 C \> A                            NM_014795.3 c.2425G \> T p.(Glu809Ter)                        Het                                                De novo            (AD) Mowat--Wilson syndrome (OMIM: 235730)                                                                                                                                                                                                                                                  Pathogenic           PVS1, PS2, PM2, PP3
  101                                             Trio         *ZEB2*       Chr 2:145157206_145157213 delCACTACCG             NM_014795.3 c.1541_1548delCGGTAGTG p.(Pro514GlnfsTer3)        Het                                                De novo            (AD) Mowat-Wilson syndrome (OMIM: 235730)                                                                                                                                                                                                                                                   Pathogenic           PVS1, PS2, PM2
  **X-linked**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     
  102                                             Trio         *DDX3X*      Chr X:41203603 C \> T                             NM_001356.4 c.976C \> T p.(Arg326Cys)                         Het                                                De novo            (XLD,XLR) Mental retardation, X-linked 102 (OMIM: 300958)                                                                                                                                                                                                                                   Pathogenic           PS2, PM1, PM2, PM5, PP2, PP3
  103                                             Singleton    *DDX3X*      Chr X:41205795\_ 41205796delAT                    NM_001356.4 c.1535_1536delAT p.(His512ArgfsTer5)              Het                                                Unknown            (XLD,XLR) Mental retardation, X-linked 102 (OMIM: 300958)                                                                                                                                                                                                                                   Pathogenic           PVS1, PM1, PM2, PM6, PS4_Moderate
  104                                             Trio         *IQSEC2*     Chr X:53263455 delG                               NM_001111125.2 c.4419delC p.(Ser1474ValfsTer21)               Het                                                De novo            (XLD) Mental retardation, X-linked 1/78 (OMIM: 309530)                                                                                                                                                                                                                                      Pathogenic           PVS1, PS2
  105                                             Trio         *IQSEC2*     Chr X:53277294 A \> G                             NM_001111125.2 c.2582 + 2T \> C p.?                           Het                                                De novo            (XLD) Mental retardation, X-linked 1/78 (OMIM: 309530)                                                                                                                                                                                                                                      Pathogenic           PVS1, PS2, PM2
  106                                             Trio         *IQSEC2*     Chr X:53277371 G \> A                             NM_001111125.2 c.2507C \> T p.(Ala836Val)                     Het                                                Unknown            (XLD) Mental retardation, X-linked 1/78 (OMIM: 309530)                                                                                                                                                                                                                                      Likely pathogenic    PS2, PM2, PS4_Moderate, PP3
  107                                             Trio         *KDM5C*      Chr X:53223464 C \> A                             NM_004187.3 c.3895G \> T p.(Glu1299Ter)                       Het                                                De novo            (XLR) Mental retardation, X-linked, syndromic, Claes--Jensen type (OMIM: 300534)                                                                                                                                                                                                            Pathogenic           PVS1, PS2, PM2
  108                                             Trio         *MECP2*      Chr X:153296860 G \> A                            NM_004992.3 c.419C \> T p.(Ala140Val)                         Hemi                                               Mat                (XLR) Mental retardation, X-linked, syndromic 13 (OMIM: 300055); (XLR) encephalopathy, neonatal severe (OMIM: 300673); (XLR) mental retardation, X-linked syndromic, Lubs type (OMIM: 300260); (XLD) Rett syndrome (OMIM: 312750) (XL) {Autism susceptibility, X-linked 3} (OMIM: 300496)   Pathogenic           PS3, PM1, PM2, PS4_Moderate, PP1, PP3, PP5
  109                                             Trio         *MED12*      Chr X:70349963 C \> G                             NM_005120.2 c.3946C \> G p.(Gln1316Glu)                       Hemi                                               Mat                (XLR) Opitz--Kaveggia syndrome (OMIM: 305450); (XLR) Lujan--Fryns syndrome (OMIM: 309520); (XLR) Ohdo syndrome, X-linked (OMIM: 300895)                                                                                                                                                     VUS                  PM2, PP3
  110                                             Trio         *NAA10*      Chr X:153197853 A \> C                            NM_003491.3 c.257T \> G p.(Leu86Arg)                          Het                                                De novo            \(XL\) ?Microphthalmia, syndromic 1 (OMIM: 309800); (XLD,XLR) Ogden syndrome (OMIM: 300855)                                                                                                                                                                                                 Pathogenic           PS2, PM1, PM2, PP2, PP3
  111                                             Trio         *PIGA*       Chr X:15339728 T \> A                             NM_002641.3 c.1355A \> T p.(Asp452Val)                        Hemi                                               De novo            (XLR) Multiple congenital anomalies-hypotonia-seizures syndrome 2 (OMIM: 300868); (XLR) paroxysmal nocturnal hemoglobinuria, somatic (OMIM: 300818)                                                                                                                                         Likely pathogenic    PS2, PM2, PP3
  112                                             Duo          *PIGA*       Chr X:15349685 G \> A                             NM_002641.3 c.368C \> T p.(Thr123Met)                         Hemi                                               Mat                (XLR) Multiple congenital anomalies-hypotonia-seizures syndrome 2 (OMIM: 300868) (XLR) Paroxysmal nocturnal hemoglobinuria, somatic (OMIM: 300818)                                                                                                                                          Likely pathogenic    PM1, PM2, PP3, PP5
  113                                             Trio         *RPS6KA3*    Chr X:20213249 G \> A                             NM_004586.2 c.340C \> T p.(Arg114Trp)                         Hemi                                               Mat                (XLD) Coffin--Lowry syndrome (OMIM: 303600)                                                                                                                                                                                                                                                 Likely pathogenic    PM1, PM2, PS4_Moderate, PP1, PP2, PP3
  114                                             Trio         *RPS6KA3*    Chr X:20179827 G \> A                             NM_004586.2 c.1894C \> T p.(Arg632Ter)                        Hemi                                               De novo            (XLD) Coffin--Lowry syndrome (OMIM: 303600)                                                                                                                                                                                                                                                 Pathogenic           PVS1, PS2, PM2, PP5
  115                                             Trio         *SMC1A*      Chr X:53410095 dupT                               NM_001281463.1 c.3053dupA p.(Arg1019AlafsTer26)               Het                                                Unknown            (XLD) Cornelia de Lange syndrome 2 (OMIM: 300590)                                                                                                                                                                                                                                           Pathogenic           PVS1, PM2

(HGVS) Human Genome Variation Society, (ACMG/AMP) American College of Medical Genetics and Genomics/Association for Molecular Pathology, (hemi) hemizygous, (het) heterozygous, (hom) homozygous, (mat) maternal, (pat) paternal, (AR) autosomal recessive, (AD) autosomal dominant, (XL) X-linked, (XLD) X-linked dominant, (XLR) X-linked recessive, (VUS) variant of uncertain significance.

^a^Proband with two disorders.

^b^Semidominant.

The proportion of the causal variant allele was documented for proband and parental samples from all cases with a provider-substantiated diagnosis by evaluation of VAF. Among the 115 provider-substantiated diagnostic cases with 117 disorders, a causal variant with a VAF \< 20% ([Supplemental Table 1](http://www.molecularcasestudies.org/lookup/suppl/doi:10.1101/mcs.a005231/-/DC1)) occurred in five probands and contributed to 4.3% \[95% CI, 1.4%--9.9%\] of our total diagnoses and 7.9% \[95% CI, 2.6%--17.6%\] of our confirmed de novo variants. As established within our pipeline, heterozygous calls (0/1 genotype) rarely deviate toward extreme allelic proportions, with 0.3% of high-confidence calls within a reference standard occurring at VAF \< 20 or VAF \> 80 ([Supplemental Fig. 1](http://www.molecularcasestudies.org/lookup/suppl/doi:10.1101/mcs.a005231/-/DC1)). In addition, causal variants in two probands were found in a mosaic state in two unaffected parents (0.3% of available parental samples). All mosaic variants were verified by Sanger sequencing analysis as evidenced by disparate peak height in the electropherogram ([Supplemental Fig. 2](http://www.molecularcasestudies.org/lookup/suppl/doi:10.1101/mcs.a005231/-/DC1)). In total, mosaic etiology in a proband, or that originating in a parent with transmission to a proband, was associated with seven out of 117 (6.0%) provider-substantiated genetic diagnoses. These mosaic variants were recurrently associated with several types of disorders, predominately involving neurodevelopmental features, including early infantile epileptic encephalopathies, intellectual disability syndromes, Coffin--Siris syndrome, and megalencephaly-polymicrogyria-polydactyly-hydrocephalus syndrome (MPPH) ([Table 3](#MCS005231MILTB3){ref-type="table"}).

DISCUSSION {#s3}
==========

We evaluated the concordance of the molecular ES diagnostic rate generated by the clinical laboratory with ordering clinical provider-substantiated diagnoses. Our results demonstrate the robust clinical utility of ES, with 91.4% of the laboratory findings reported as likely causal for the proband phenotype resulting in a clinically confirmed diagnosis by the ordering provider. This concordance may increase over time, as four laboratory-reported diagnostic cases were still under consideration in the patient differential. The high concordance rate may be attributable to the detailed clinical feature information form submitted by an experienced clinical geneticist or genetic counselor at the time of ES ordering, additional curation of the medical record as performed by the variant analysis team or laboratory genetic counselor to enable a phenotype-informed variant analysis approach, and the multidisciplinary expertise achieved by group evaluation of annotated, filtered variants in a case conference setting. Within our primarily pediatric population, we obtained a 32.2% diagnostic yield, with 64.9% of causal variants identified by trio analysis confirmed as de novo. These numbers are in line with previously reported exome and genome sequencing diagnostic yields (average = 31%) and de novo rates (average = 44%) ([@MCS005231MILC10]). In comparison to other large clinical exome sequencing cohorts, our study found a similar rate of cases submitted for trio analysis. In addition, the distribution of AD, AR, and XL inheritance patterns of causal variants were also comparable ([@MCS005231MILC53], [@MCS005231MILC54]; [@MCS005231MILC25]; [@MCS005231MILC14]; [@MCS005231MILC40]).

Of the 115 diagnostic cases, we confirmed mosaicism of a disease-associated variant in five probands and two parental samples. The contribution of parental mosaicism may be higher, given that trio analyses were available for 74.8% of our cases. The frequency of mosaicism in our cohort is higher than what has previously been reported in unselected clinical exome sequencing cohorts ([@MCS005231MILC53]; [@MCS005231MILC40]; [@MCS005231MILC9]). Several differences between our study and previous reports may contribute to this difference, including sequencing in a hospital-based laboratory representing a pediatric patient population referred by clinical geneticists within a single institution, stringent quality control metrics for sequencing data (including both assay and variant quality measures), diagnostic yield based on EMR clinical substantiation versus solely a laboratory-defined molecular diagnostic yield, and manual evaluation of all assessed variants with specific review of aligned reads and variant characteristics in proband and parental samples.

Our positive mosaic findings contributed to several types of disorders associated with neurodevelopmental features including Coffin--Siris syndrome (*n* = 2), early infantile epileptic encephalopathy (*n* = 2), intellectual disability syndromes (*n* = 2), and the brain overgrowth syndrome MPPH (*n* = 1). The presence of mosaicism in these patients is consistent with the reported association of mosaic variants within these types of disorders ([@MCS005231MILC24]; [@MCS005231MILC26]; [@MCS005231MILC29]; [@MCS005231MILC50]). The enrichment of our pediatric ES population for various neurodevelopmental features, such as developmental delays, cognitive impairment, and autistic behavior, also may have contributed to the high prevalence of mosaicism seen within this cohort.

Identifying that a disease-causing variant is mosaic can have several implications when counseling families. Although the presence of mosaicism is generally unable to predict disease severity, as often only a single tissue type is available for study, it can be informative in providing a clinical explanation for a proband with a mild presentation. In this cohort, detection of mosaicism provided a mechanism to explain a mildly affected male diagnosed with the X-linked disorder, early infantile epileptic encephalopathy 2, primarily seen in females (Case 2). Identifying mosaicism in proband or parental samples is of particular importance to inform recurrence risk in future pregnancies. Evaluating parental samples for the presence of mosaicism can also be beneficial for providing an explanation for why a parent positive for pathogenic variant may be mildly symptomatic or unaffected, as evidenced in this series by the unaffected mother with an *IQSEC2* mosaic variant, which was hemizygous in the affected proband, as well as his affected brother (Case 4, previously reported by [@MCS005231MILC4]).

Mosaic variants can be challenging to detect clinically because of several factors, and consensus guidelines addressing how to detect, assess, and report mosaicism are not currently available. These variants can occur at very low frequencies and thus may be below the threshold of detection if coverage or read depth is insufficient at the affected residue. [@MCS005231MILC1] modeled that the probability of detecting mosaicism at 100× coverage is \>90% for variants occurring at 10% VAF or higher. However, the ability to detect these variants decreases considerably with decreasing read depth. The higher sequence depth in coding regions typically achieved by exome sequencing thus offers an advantage for detecting mosaicism compared to genome sequencing, because of cost-related limitations to genome sequencing read depth. Despite sufficient coverage across a given region, if the variant is present in a limited number of reads, it may be below the sensitivity of the variant caller software. In our cohort, one of the mosaic variants in a parental sample (Case 6), the *ARID2* variant at 4% VAF, was not detected by the variant caller and came to attention during manual review of reportable variants within aligned sequencing reads. This highlights the utility in manual review of variant calls within the aligned reads to evaluate variant authenticity.

Alternatively, identifying an authentic mosaic variant can also present a challenge. With MPS, false-positive variants may occur by several means. These include biologic contamination during sample acquisition, nucleic acid extraction, or library preparation, low-level admixture during sequencing, or as a result of sample carryover from prior sequencing runs, as well as polymerase chain reaction (PCR) or sequencing artifacts (incorporation errors and library chimeras). Additionally, index hopping can result in false positive calls at very low-level as single-indexed reads can incur misassignment of indices within multiplexed libraries, a phenomenon known to be enhanced on patterned flow cells in short-read sequencing chemistries. The confounding variable of index hopping in the setting of trio analyses can be decreased by the use of dual indexing of libraries ([@MCS005231MILC11]). To increase confidence in calling mosaicism and rare, low-frequency variants, the addition of dual-indexed libraries containing unique identifiers known as molecular barcodes ([@MCS005231MILC21]; [@MCS005231MILC45]) allows discrimination of improperly indexed libraries and random errors. In this study, all de novo and mosaic variants called with single-indexed libraries were confirmed by Sanger sequencing. Evidence of the low-level variant allele could be visualized for all mosaic variants by review of peak heights in the electropherogram. A priori knowledge of suspected mosaicism facilitated review of Sanger sequencing data and enabled scrutiny of allelic peak heights, including the variant allele relative to background. Thus, data points from two orthogonal methodologies (MPS and Sanger) were considered prior to report out of a mosaic call. The variant with a VAF of 4% in a maternal sample (Case 6) was visualized by Sanger sequencing, despite being below the threshold typically appreciable by this method (∼10%--20%), because of the nature of the variant (2-nt deletion), as well as prior observation of the heterozygous variant in the proband. However, if the VAF is too low to be appreciable by Sanger, high-depth amplicon sequencing or other quantitative approaches including digital droplet PCR could be used. The testing of alternative tissue sources can also be considered to aid in confirming suspected mosaicism in patients, although multiple tissue sources may be required, and may be impractical or impossible to obtain. Authentic mosaic variants with high VAFs can also be challenging to detect, as they may be mistaken for heterozygous calls that deviate from the expected 50% VAF because of technical variation and platform bias ([@MCS005231MILC1]).

Outside of technical limitations of the assay, mosaic variants can go undetected when the variant is confined to specific tissue types. In these cases, sequencing of the affected tissues is required for detection. Confinement of mosaicism in a parent to predominately or exclusively germline cells would also go undetected by clinical ES trio analysis and typically only comes to light in instances of multiple affected children from an otherwise unaffected parent.

In conclusion, our study highlights two years of an ongoing ES assay within a pediatric tertiary care institution and emphasizes the utility of clinical-provider engagement in ES test ordering and phenotypic curation, as demonstrated by the strong concordance of laboratory-reported and ordering provider-substantiated diagnostic yield. Additionally, we demonstrate that mosaicism is an important contributor to disease-causing variation identified by ES within the pediatric population. Given that our diagnostic yield of mosaic variants exceeds those reported by other ES studies, vigilant manual review of variant calls by a highly skilled variant analysis team and clinical laboratory directors may be a key differentiator in detecting somatic mosaic events. This must occur in concert with adequate read depth and breadth of the assay, appropriate bioinformatic processing parameters, and in consideration of the proband\'s clinical characteristics to attribute causality. As we begin to appreciate the expanding role of mosaicism in genetic disease, further research on the types of disorders with mosaicism, clinical implications, and optimal laboratory practices for identifying and reporting mosaicism are needed.

METHODS {#s4}
=======

Sequencing, Bioinformatics, and Quality Control {#s4a}
-----------------------------------------------

Proband and parental peripheral blood samples were submitted for ES to The Steve and Cindy Rasmussen Institute for Genomic Medicine at Nationwide Children\'s Hospital, Columbus, Ohio. Prior to ES studies, microarray analysis was previously performed on the submitted proband, unless deemed to not be clinically indicated by the ordering provider (5% of the cohort). Genomic DNA was extracted using the Puregene DNA isolation kit according to the manufacturer protocol (QIAGEN) or EZ1 DNA isolation kit (QIAGEN), with two separate DNA extractions performed per each submitted proband and parental sample to facilitate identity and provenance analyses. Genotyping of 30 autosomal loci representing single-nucleotide variants with high population minor allele frequency was performed in the parental and proband samples using a custom Agena MassArray panel (Agena). Subsequently, a comparison of the Agena-derived genotype data was performed relative to aligned sequencing read data derived by MPS to further ensure sample provenance throughout the extraction, library preparation, sequencing, and bioinformatic analysis stages, as well as to verify familial relationships.

Libraries were subject to target capture using SureSelect Human All Exon V6 (Agilent) followed by paired-end 101- or 151-bp sequencing to 137× mean depth on a HiSeq 2500 or HiSeq 4000 (Illumina), with 96.5% of targeted bases at 20× or greater ([Supplemental Table 2](http://www.molecularcasestudies.org/lookup/suppl/doi:10.1101/mcs.a005231/-/DC1)). Sequencing data were demultiplexed and analyzed by GenomeNext (Columbus, OH) v1.1, which performs alignment to the reference sequence (GRCh37/hg19 Feb 2009), deduplication, and single sample variant calling with GATK Unified Genotyper 1.6--13 via the Churchill secondary analysis pipeline ([@MCS005231MILC18]). Mitogen (Sunquest) was used for annotation and tertiary analysis filtering informed by clinician-provided phenotypes, which were converted into HPO terms ([@MCS005231MILC22]).

As standard of practice in our exome workflow, aligned sequencing reads in the BAM file were reviewed at all assessed variants using the Integrative Genomics Viewer v2.3-2.4.4 (Broad) ([@MCS005231MILC43]). This allowed for a review of variant authenticity and encompassed an examination of read counts and strandedness, location of the variant within the read, VAF, homology, read quality, and mapping. Manual review of read-aligned proband data was performed relative to review of identity-confirmed parental sequence to allow for side-by-side comparison, with IGV alignment preferences set to allow for display of coverage allele-fraction threshold at 2% and retention of soft-clipped reads. Genomic regions with known homology as defined by [@MCS005231MILC30] have been incorporated into ES analysis through BED file track definitions to visually flag the level of homology of the local region in IGV. Parentage was confirmed in our data set for all de novo calls, with familial relationships established by genotyping per our standard workflow. Hemizygous variants were X-linked variants identified in \>95% of reads in male patients. Homozygous calls applied to autosomal variants in \>95% of reads. Variants deviating to the extreme of VAF \<20 or \>80 were considered suspicious for mosaicism, and subsequently underwent orthogonal testing by Sanger sequencing.

Sanger sequencing was performed on proband and available parental samples for all de novo variants and suspected mosaic variants identified as likely causal for the proband phenotype. Analysis by Sanger was used to distinguish from MPS or PCR artifact, and verify reduction in allelic ratio as visualized by disparate peak heights for mosaicism. For Sanger sequencing, PCR amplification of the region of interest was followed by purification using the QIAquick purification kit (QIAGEN). Forward and reverse sequencing reactions were performed with the Big Dye v3.1 terminator mix (ThermoFisher). Sequencing was performed on an Applied Biosystems 3130 or 3730 instrument (ThermoFisher). Mosaic variants were confirmed by observation of a nonreference allele with a disparate peak height during Sanger analysis.

Variant Interpretation {#s4b}
----------------------

Custom scripting allowed for enrichment of variant attribute data including disease association and phenotype overlap. For each proband, the annotated filtered variant list was evaluated at a case conference attended by laboratory directors, genetic counselors, variant scientists, residents, fellows, and geneticists, including the ordering provider, when available. Variants that met group consensus were assessed according to ACMG/AMP recommendations ([@MCS005231MILC41]). Following assessment, variants are reported as either likely causal for proband phenotype or as findings of undetermined clinical relevance to the proband phenotype based upon strength of phenotype overlap with the associated disease at the discretion of the ABMGG board-certified signing director. Laboratory diagnostic yield was defined as the number of cases with a variant or variants reported as likely causal for the proband phenotype. Concordance between the laboratory and the ordering provider as to reported variant-associated disease causality was examined via clinical documentation in the EMR. Variants were considered clinically confirmed as causal if the ordering provider attributed some or all features in the proband to the variant(s).

ADDITIONAL INFORMATION {#s5}
======================

Data Deposition and Access {#s5a}
--------------------------

The mosaic variants were submitted to ClinVar (<http://www.ncbi.nlm.nih.gov/clinvar/>) under accession numbers SCV001161761.1, SCV001161762.1, SCV001161763.1, SCV000864353.2, SCV001161764.1, SCV001161765.1, and SCV001161766.1. Additional variants from the 117 diagnostic cases have been deposited to ClinVar under submitter Institute for Genomic Medicine (IGM) Clinical Laboratory, Nationwide Children\'s Hospital. Details are provided in the [supplemental material](http://www.molecularcasestudies.org/lookup/suppl/doi:10.1101/mcs.a005231/-/DC1). Deposition of raw sequencing data is not permitted based on patient consent.
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